ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

3.04USD-0.33 (-9.79%)Market Closed

Market Summary

USD3.04-0.33

Market Closed

-9.79%

ALLO Stock Price

View Fullscreen

ALLO RSI Chart

ALLO Valuation

Market Cap

514.0M

Price/Earnings (Trailing)

-1.57

Price/Sales (Trailing)

5.4K

EV/EBITDA

-2.74

Price/Free Cashflow

-2.15

ALLO Price/Sales (Trailing)

ALLO Profitability

EBT Margin

-270531.58%

Return on Equity

-63.89%

Return on Assets

-50.91%

Free Cashflow Yield

-46.54%

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

95.0K

Rev. Growth (Yr)

-19.23%

Rev. Growth (Qtr)

-4.55%

ALLO Earnings

Earnings (TTM)

-327.3M

Earnings Growth (Yr)

11.82%

Earnings Growth (Qtr)

-37.71%

Breaking Down ALLO Revenue

Last 7 days

-13.4%

Last 30 days

-29.1%

Last 90 days

-5%

Trailing 12 Months

-45.7%

How does ALLO drawdown profile look like?

ALLO Financial Health

Current Ratio

12.38

ALLO Investor Care

Shares Dilution (1Y)

17.02%

Diluted EPS (TTM)

-2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	147.0K	105.0K	100.0K	95.0K
2022	85.6M	57.1M	28.6M	156.0K
2021	0	0	0	114.1M
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Allogene Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	moore timothy l.	sold (taxes)	-60,188	3.4671	-17,360	chief technical officer
Mar 14, 2024	chang david d	sold (taxes)	-231,192	4.33	-53,393	president and ceo
Jan 30, 2024	parker geoffrey m.	bought	683	3.595	190	chief financial officer
Jan 25, 2024	chang david d	acquired	-	-	317,800	president and ceo
Jan 25, 2024	parker geoffrey m.	acquired	-	-	29,400	chief financial officer
Jan 25, 2024	roberts zachary	acquired	-	-	140,000	evp of r&d
Jan 25, 2024	moore timothy l.	acquired	-	-	96,600	chief technical officer
Jan 25, 2024	belldegrun arie	acquired	-	-	211,973	-
Jan 25, 2024	douglas earl martin	acquired	-	-	41,800	svp, general counsel
Jan 22, 2024	roberts zachary	sold (taxes)	-78,375	3.1744	-24,690	evp of r&d

Which funds bought or sold ALLO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.38	-11,000	12,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	1,681	134,878	-%
Apr 22, 2024	SHIKIAR ASSET MANAGEMENT INC	unchanged	-	19,000	70,000	0.02%
Apr 19, 2024	BOURGEON CAPITAL MANAGEMENT LLC	added	12.82	92,937	255,684	0.05%
Apr 18, 2024	Clarity Wealth Advisors, LLC	unchanged	-	19,696	69,875	0.02%
Apr 18, 2024	West Oak Capital, LLC	unchanged	-	-	-	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-26,887	-	-%
Apr 16, 2024	CALTON & ASSOCIATES, INC.	sold off	-100	-67,602	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	75.89	167,661	283,349	0.01%
Apr 12, 2024	Navalign, LLC	unchanged	-	94,960	336,882	0.11%

Are Funds Buying or Selling ALLO?

Are funds buying ALLO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALLO

No. of Funds

Unveiling Allogene Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	chang david d	5.8%	9,964,347	SC 13G/A
Feb 14, 2024	belldegrun arie	5.8%	9,895,903	SC 13G/A
Feb 13, 2024	vanguard group inc	5.37%	9,030,825	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	10,001,804	SC 13G/A
Jan 23, 2024	state street corp	1.44%	2,427,284	SC 13G/A
Oct 25, 2023	pfizer inc	13.14%	22,032,040	SC 13D/A
Jul 10, 2023	fmr llc	-	0	SC 13G
Feb 13, 2023	chang david d	5.7%	8,427,632	SC 13G
Feb 13, 2023	belldegrun arie	6.1%	8,858,861	SC 13G/A

Recent SEC filings of Allogene Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 22, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	10-K/A	Annual Report
Mar 14, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	8-K	Current Report

Peers (Alternatives to Allogene Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Allogene Therapeutics Inc News

Latest updates

Allogene Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-4.5%	21.00	22.00	22.00	30.00	26.00	27.00	64.00	37,858	75,651	49.00	44.00	38,345	-
Operating Expenses	35.1%	85,130	63,018	80,562	99,122	96,421	82,538	76,680	80,053	73,944	77,719	71,073	71,546	69,362
S&GA Expenses	1.1%	17,224	17,041	18,524	18,884	21,002	18,897	19,509	19,897	19,961	18,999	18,783	16,363	17,134
R&D Expenses	18.9%	54,661	45,977	62,038	80,238	75,419	63,641	57,171	60,156	53,983	58,720	52,290	55,183	52,228
EBITDA Margin	-95.5%	-2.56	-1.31	-1.27	-1.04	-998.81*	-24.64*	-12.55*	-8.46*	-6.41*	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-68,570
EBT Margin	-95.8%	-2.71	-1.38	-1.34	-1.10	-1.06	-26.21*	-13.27*	-8.88*	-6.68*	-	-	-	-
Net Income	-37.7%	-85,778	-62,287	-79,232	-99,968	-97,275	-84,242	-80,290	-78,607	86.00	-78,186	-70,936	-33,015	-134,730
Net Income Margin	-92.5%	-3.44	-1.79	-1.85	-1.50	-1.37	-31.89*	-15.89*	-10.50*	-6.68*	-	-	-	-
Free Cashflow	3.0%	-53,888	-55,542	-62,145	-67,674	-63,788	-47,878	-43,905	-70,139	-46,172	-52,225	-52,072	-55,789	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.9%	643	713	773	750	822	894	956	978	1,051	1,079	1,127	1,179	1,228	1,223	1,259	689	718	696	734	749	774
Current Assets	-3.0%	459	473	502	481	529	569	513	470	471	503	602	716	845	854	910	504	545	510	512	477	468
Cash Equivalents	20.1%	83.00	69.00	155	110	62.00	74.00	96.00	85.00	173	199	233	246	193	168	285	140	179	165	117	97.00	94.00
Net PPE	-3.3%	99.00	103	106	110	113	114	117	120	123	126	125	123	119	103	85.00	66.00	56.00	46.00	36.00	20.00	9.00
Liabilities	-1.6%	131	133	152	158	155	151	149	113	126	109	103	109	148	104	95.00	82.00	89.00	76.00	78.00	68.00	71.00
Current Liabilities	-1.1%	37.00	37.00	55.00	59.00	54.00	48.00	44.00	37.00	48.00	53.00	46.00	55.00	94.00	50.00	41.00	27.00	33.00	33.00	38.00	27.00	29.00
Shareholder's Equity	-11.8%	512	581	621	592	667	743	806	865	925	970	1,024	1,070	1,013	1,119	1,163	607	629	620	656	681	703
Retained Earnings	-5.8%	-1,562	-1,476	-1,414	-1,334	-1,234	-1,137	-1,053	-973	-894	-828	-750	-679	-712	-577	-511	-450	-396	-335	-284	-243	-211
Additional Paid-In Capital	0.8%	2,075	2,059	2,039	1,933	1,912	1,894	1,871	1,848	1,822	1,799	1,774	1,749	1,726	1,695	1,673	1,055	1,024	953	938	923	914
Shares Outstanding	0.3%	169	168	167	146	144	144	144	144	143	137	134	132	-	-	-	-	-	-	-	-	-
Float	-	-	-	557	-	-	-	1,009	-	-	-	2,254	-	-	-	3,509	-	-	-	1,601	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	3.3%	-53,707	-55,530	-61,857	-66,639	-62,096	-47,655	-42,531	-68,237	-45,436	-48,878	-41,170	-49,328	-9,975	-37,588	-26,721	-40,809	-50,267	-31,935	-24,892	-30,256	-21,481
Share Based Compensation	-0.8%	15,233	15,354	16,594	18,770	17,246	21,148	22,891	22,315	22,036	20,856	21,134	16,792	16,453	17,823	16,770	14,215	13,874	12,835	11,487	7,867	5,871
Cashflow From Investing	296.9%	67,461	-34,267	17,160	112,935	49,597	24,905	54,034	-22,377	29,250	13,013	24,594	96,798	22,210	-83,355	-428,971	-15,007	7,929	78,775	44,492	32,888	-313,388
Cashflow From Financing	-96.4%	155	4,285	89,524	1,731	46.00	1,066	24.00	1,814	322	2,383	3,214	6,044	12,978	3,852	600,175	16,586	56,474	1,566	236	684	344,522

ALLO Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended			61 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue - related party	$ 156	$ 114,089	$ 0
Operating expenses:
Research and development	256,387	220,176	192,987
General and administrative	79,305	74,105	65,256
Total operating expenses	335,692	294,281	258,243
Loss from operations	(335,536)	(180,192)	(258,243)
Other income (expense), net:
Interest and other income, net	4,566	1,714	9,164
Other expenses	(9,444)	(3,573)	(67,302)
Total other income (expense), net	(4,878)	(1,859)	(58,138)
Net loss	(340,414)	(182,051)	(316,381)	$ (1,235,000)
Other comprehensive income:
Net unrealized loss on available-for-sale investments	(7,359)	(2,835)	(877)
Net comprehensive loss	$ (347,773)	$ (184,886)	$ (317,258)
Net loss per share, basic (in dollars per share)	$ (2.38)	$ (1.34)	$ (2.63)
Net loss per share, diluted (in dollars per share)	$ (2.38)	$ (1.34)	$ (2.63)
Weighted-average number of shares used in computing net loss per share, basic (in shares)	143,147,165	135,820,386	120,370,177
Weighted-average number of shares used in computing net loss per share, diluted (in shares)	143,147,165	135,820,386	120,370,177

ALLO Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 61,904	$ 173,314
Short-term investments	455,416	283,988
Prepaid expenses and other current assets	11,504	14,021
Total current assets	528,824	471,323
Long-term investments	59,151	352,179
Operating lease right-of-use asset	83,592	58,030
Property and equipment, net	112,839	122,990
Restricted cash	10,292	10,292
Other long-term assets	9,564	5,815
Equity method investments	17,317	30,199
Total assets	821,579	1,050,828
Current liabilities:
Accounts payable	13,890	10,255
Accrued and other current liabilities	39,743	37,496
Deferred revenue	95	156
Total current liabilities	53,728	47,907
Lease liability, noncurrent	95,122	69,929
Other long-term liabilities	5,847	7,792
Total liabilities	154,697	125,628
Commitments and Contingencies (Notes 6 and 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 authorized as of December 31, 2022 and December 31, 2021; no shares were issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value: 400,000,000 and 200,000,000 shares authorized as of December 31, 2022 and December 31, 2021, respectively; 144,438,304 and 142,623,065 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	144	142
Additional paid-in capital	1,911,632	1,822,179
Accumulated deficit	(1,234,968)	(894,554)
Accumulated other comprehensive loss	(9,926)	(2,567)
Total stockholders’ equity	666,882	925,200
Total liabilities and stockholders’ equity	$ 821,579	$ 1,050,828
Common stock, shares authorized (in shares)	400,000,000	200,000,000

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Dr. David D. Chang M.D., Ph.D.
WEBSITE	allogene.com
INDUSTRY	Biotechnology
EMPLOYEES	359

Allogene Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Allogene Therapeutics Inc? What does ALLO stand for in stocks?

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allogene Therapeutics Inc (ALLO)?

As of Wed Apr 24 2024, market cap of Allogene Therapeutics Inc is 514.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers. The fair value of Allogene Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allogene Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allogene Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALLO is over valued or under valued. Whether Allogene Therapeutics Inc is cheap or expensive depends on the assumptions which impact Allogene Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLO.

What is Allogene Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ALLO's PE ratio (Price to Earnings) is -1.57 and Price to Sales (PS) ratio is 5.41 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.